<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00898963</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000544400</org_study_id>
    <secondary_id>ECOG-E1496T1</secondary_id>
    <nct_id>NCT00898963</nct_id>
  </id_info>
  <brief_title>Biomarkers in Patients With Stage III or Stage IV Follicular Lymphoma Treated on Clinical Trial E-1496</brief_title>
  <official_title>Identification of Biomarkers in Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECOG-ACRIN Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help&#xD;
      doctors identify and learn more about biomarkers related to cancer. It may also help doctors&#xD;
      predict how patients respond to treatment.&#xD;
&#xD;
      PURPOSE: This laboratory study is looking at biomarkers in patients with stage III or stage&#xD;
      IV follicular lymphoma treated on clinical trial E-1496.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Correlate gene expression profiles with progression-free survival (PFS) of patients with&#xD;
           stage III or IV follicular lymphoma treated with cyclophosphamide, vincristine, and&#xD;
           prednisone with or without rituximab on clinical trial E-1496.&#xD;
&#xD;
        -  Determine if immunoglobulin Fc-gamma receptor polymorphisms are predictive of PFS in&#xD;
           these patients.&#xD;
&#xD;
        -  Assess the significance of the microenvironment by constructing tissue microarrays of&#xD;
           follicular lymphoma and immunostaining with relevant biomarkers.&#xD;
&#xD;
        -  Correlate relevant biomarkers with clinical features, response, and PFS.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Tissue samples are analyzed by gene expression profiling, microarrays to predict gene&#xD;
      expression, immunohistochemistry, and immunoglobulin Fc-gamma receptor polymorphism analysis&#xD;
      for biological markers.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 175 samples will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 18, 2007</start_date>
  <completion_date type="Actual">February 11, 2011</completion_date>
  <primary_completion_date type="Actual">February 11, 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of gene expression profiles with progression-free survival (PFS)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prediction of PFS by immunoglobulin Fc-gamma receptor polymorphisms as assessed by immunohistochemistry</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of significance of microenvironment by constructing tissue microarrays and immunostaining with relevant biomarkers</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of relevant biomarkers with clinical features, response, and PFS</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <enrollment type="Actual">175</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Samples submitted for research from patients participating in E1496&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of follicular lymphoma&#xD;
&#xD;
               -  Stage III or IV disease&#xD;
&#xD;
          -  Received cyclophosphamide, vincristine, and prednisone with or without rituximab on&#xD;
             clinical trial E-1496&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall D. Gascoyne, MD</last_name>
    <role>Study Chair</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

